Selective Histone Deacetylase Inhibitors with Anticancer Activity

被引：50

作者：

Ma, Nan ^{[1
,2
,3
]}

Luo, Ying ^{[4
]}

Wang, Ying ^{[2
]}

Liao, Chenzhong ^{[4
]}

Ye, Wen-Cai ^{[2
,3
]}

Jiang, Sheng ^{[1
]}

机构：

[1] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Lab Med Chem, Guangzhou 510530, Guangdong, Peoples R China

[2] Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China

[3] China Pharmaceut Univ, Dept Nat Med Chem, Nanjing 210009, Jiangsu, Peoples R China

[4] Hefei Univ Technol, Sch Med Engn, Hefei 230009, Anhui, Peoples R China

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2016年 / 16卷 / 04期

关键词：

Class I; Class II; Class III; HDAC; HDAC1; HDAC6; Selective histone deacetylase inhibitors; BIOLOGICAL EVALUATION; CLASS-I; CLICK CHEMISTRY; CYCLIC TETRAPEPTIDES; HDAC INHIBITORS; LARGAZOLE ANALOGS; TRICHOSTATIN-A; HIGHLY POTENT; CANCER-CELLS; DESIGN;

D O I：

10.2174/1568026615666150813145629

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

HDAC inhibitors (HDACIs), which can be used to kill cancer cells through inhibiting histone deacetylase activity or altering the structure of chromatin, have emerged as efficacious agents in the treatment of cancer. With SAHA, FK228, belinostat and panobinostat approved by the FDA, displaying satisfying activity in both haematological and solid tumors of various tissues, efforts to create selective HDACIs have been attracted attention over the past several years. Herein, we mainly review the progress of selective HDAC inhibitors including class-selective and isoform-selective HDAC inhibitors.

引用

页码：415 / 426

页数：12

共 50 条

[21] Isoform-selective histone deacetylase inhibitors
Bieliauskas, Anton V.
Pflum, Mary Kay H.
CHEMICAL SOCIETY REVIEWS, 2008, 37 (07) : 1402 - 1413
[22] Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, Jelena
Simoben, Conrad V.
Praetorius, Lucas
Bulbul, Emre F.
Robaa, Dina
Sippl, Wolfgang
CHEMMEDCHEM, 2021, 16 (09) : 1336 - 1359
[23] Isoform-selective histone deacetylase inhibitors
Itoh, Yukihiro
Suzuki, Takayoshi
Miyata, Naoki
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (06) : 529 - 544
[24] Largazole analogs as selective histone deacetylase inhibitors
Al-Hamashi, Ayad
Almaliti, Jehad
Farrell, Robert
Tillekeratne, Viranga
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
[25] Discovery of histone deacetylase 8 selective inhibitors
Tang, Weiping
Luo, Tuoping
Greenberg, Edward F.
Bradner, James E.
Schreiber, Stuart L.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (09) : 2601 - 2605
[26] Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Gabrielli, B. G.
Johnstone, R. W.
Saunders, N. A.
CURRENT CANCER DRUG TARGETS, 2002, 2 (04) : 337 - 353
[27] A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Rajak, H.
Singh, A.
Raghuwanshi, K.
Kumar, R.
Dewangan, P. K.
Veerasamy, R.
Sharma, P. C.
Dixit, A.
Mishra, P.
CURRENT MEDICINAL CHEMISTRY, 2014, 21 (23) : 2642 - 2664
[28] Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis
Mo, Hualong
Zhang, Ruiqiang
Chen, Yajun
Li, ShuTing
Wang, Yao
Zou, Wenbo
Lin, Qiman
Zhao, Deng-Gao
Du, Yarong
Zhang, Kun
Ma, Yan-Yan
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 243
[29] Histone deacetylase inhibitors: A novel target of anticancer therapy (Review)
Kouraklis, G
Theocharis, S
ONCOLOGY REPORTS, 2006, 15 (02) : 489 - 494
[30] Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
Miller, Claudia P.
Singh, Melissa M.
Rivera-Del Valle, Nilsa
Manton, Christa A.
Chandra, Joya
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011,

← 1 2 3 4 5 →